Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications
about
Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptorsExtensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionLocalization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive EpitopesFeasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplexMouse models for filovirus infectionsViral quasispecies evolutionMucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeCross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in BangkokInfection-Enhancing and -Neutralizing Activities of Mouse Monoclonal Antibodies against Dengue Type 2 and 4 Viruses Are Controlled by Complement LevelsFc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cellsHumoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle AntigensA Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever ModelNeutralizing antibody response and SARS severityHuman monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutantsBacteriophages and Their Immunological Applications against Infectious Threats.Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.Characterization of the envelope glycoprotein of a novel filovirus, lloviu virusNon-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease.Antibodies against a surface protein of Streptococcus pyogenes promote a pathological inflammatory response.Epidemiology of Dengue Among Children Aged < 18 Months-Puerto Rico, 1999-2011.Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cellsProgress in the identification of dengue virus entry/fusion inhibitorsComplement and viral pathogenesisEnterovirus 71 infection of monocytes with antibody-dependent enhancementProtective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialAntibody dependent enhancement infection of enterovirus 71 in vitro and in vivo.Foot-and-mouth disease virus exhibits an altered tropism in the presence of specific immunoglobulins, enabling productive infection and killing of dendritic cells.Antibody-dependent enhancement of Marburg virus infectionFcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus InfectionMyd88-dependent toll-like receptor 7 signaling mediates protection from severe Ross River virus-induced disease in miceAssociation of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccinationNeutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunityMapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodiesHumoral immunity to HIV-1: neutralization and beyond.
P2860
Q21090770-3346025D-BA44-42A5-BBD9-8B0541FBC53CQ21245045-77C3521C-136C-4C1C-BF8F-A869CEF253EEQ24289053-634692C2-1002-4FDA-A826-B893F5DD2FCCQ24737461-6C13935E-9E9C-4D3D-A850-D970262E15EBQ27011569-AC195E32-67C1-42A4-A14E-8E1E6633DC79Q27013917-6BA3AE8D-3DB3-4131-9AD1-60446A23E323Q27318151-9C4B26C2-BF08-454E-B7E1-1F555ACD2FF8Q27477511-5A4EF4E7-647A-4DFB-99B0-3DB5B23FE767Q27485321-B72AA0EC-96B0-4A41-86E2-DBBB99D740ECQ27486208-32A8241F-FC95-42F2-BE80-4DA86E0D2D36Q27488243-B8D8EF9E-A602-454D-A13E-A91A5859C233Q27490166-B6343BC9-7ED0-41E4-BA2B-C6580386F042Q28385241-BC22BA2A-535D-402D-B51C-93BDCDAADA4FQ28768526-87D942D2-1320-49B5-8F4D-826A67D13595Q30234522-87E78410-9807-4FF9-9D6B-733C0D975498Q30388012-AC99148E-5553-48B1-95BC-98378D815562Q30391355-74FDC326-1605-465E-9044-8DAED28058EEQ30395259-CC7D17B7-7A38-4A6C-BC43-0FAFD3CE3752Q33369063-4E87C256-4102-4702-9911-868A36E71696Q33428741-991465E5-2593-4B62-A84A-9673CB8FFB74Q33900233-9535D874-3034-4CF1-A160-DB1108BE93DCQ33934442-C6567CCA-E55D-4E4B-BEA3-D30772792AC0Q33955239-BBFB35B8-5831-43BA-B7F9-1B8D35DCE498Q34054616-9831464E-D561-4EC1-8A50-CD52FE03A22FQ34162421-16F343F8-45BA-4AB5-BFDF-E72F66894F54Q34189997-F04B5D9B-B755-4BB8-9DD5-DC34399B5F54Q34257290-38389211-B76E-4829-87BC-284A79428AE8Q34463780-16D9EEF3-7AE6-4B9F-95DD-B536AA069165Q34571072-961267A8-D5C6-4CE2-89E5-A9BA5568E8C3Q34692967-248CA251-84EA-4EE6-A92E-63EB024765B3Q34741667-090FC557-CB0D-4A51-AE91-F762CC120C1FQ35299989-2058D85D-F973-4ACE-91C0-1778BFF01D67Q36236428-6BD8F65E-3B34-4C4C-BE4B-65AD073899C0Q36276696-3329F654-6BD4-45E9-AE15-5EFCFBFA7581Q36305326-25A614D4-D6F9-46A6-B8A3-64D70EBAF42EQ36404194-D47F1EF6-BEB6-4C83-8941-4133EEDCFC4CQ36421192-DC58C6F8-82DD-42BD-9067-E6936F5DC3B1Q36780133-E874932D-C49E-42D1-986F-94C6328C8D8FQ36786293-C1EDFB80-3F1B-4621-B995-2E6D0B1A6DD8Q36863847-3BD0D949-9959-4B74-A2B7-0A6EB575B0A7
P2860
Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antibody-dependent enhancement ...... nisms and in vivo implications
@ast
Antibody-dependent enhancement ...... nisms and in vivo implications
@en
Antibody-dependent enhancement ...... nisms and in vivo implications
@nl
type
label
Antibody-dependent enhancement ...... nisms and in vivo implications
@ast
Antibody-dependent enhancement ...... nisms and in vivo implications
@en
Antibody-dependent enhancement ...... nisms and in vivo implications
@nl
prefLabel
Antibody-dependent enhancement ...... nisms and in vivo implications
@ast
Antibody-dependent enhancement ...... nisms and in vivo implications
@en
Antibody-dependent enhancement ...... nisms and in vivo implications
@nl
P2860
P3181
P356
P1476
Antibody-dependent enhancement ...... nisms and in vivo implications
@en
P2093
Ayato Takada
P2860
P304
P3181
P356
10.1002/RMV.405
P407
P577
2003-01-01T00:00:00Z